Cargando…
Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802533/ https://www.ncbi.nlm.nih.gov/pubmed/29339727 http://dx.doi.org/10.1038/s41408-017-0044-5 |
| _version_ | 1783298537806626816 |
|---|---|
| author | Mozas, Pablo Rivas-Delgado, Alfredo Baumann, Tycho Villamor, Neus Ortiz-Maldonado, Valentín Aymerich, Marta Costa, Dolors Navarro, Alba Giné, Eva López-Guillermo, Armando Montserrat, Emili Delgado, Julio |
| author_facet | Mozas, Pablo Rivas-Delgado, Alfredo Baumann, Tycho Villamor, Neus Ortiz-Maldonado, Valentín Aymerich, Marta Costa, Dolors Navarro, Alba Giné, Eva López-Guillermo, Armando Montserrat, Emili Delgado, Julio |
| author_sort | Mozas, Pablo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5802533 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-58025332018-02-08 Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia Mozas, Pablo Rivas-Delgado, Alfredo Baumann, Tycho Villamor, Neus Ortiz-Maldonado, Valentín Aymerich, Marta Costa, Dolors Navarro, Alba Giné, Eva López-Guillermo, Armando Montserrat, Emili Delgado, Julio Blood Cancer J Correspondence Nature Publishing Group UK 2018-01-16 /pmc/articles/PMC5802533/ /pubmed/29339727 http://dx.doi.org/10.1038/s41408-017-0044-5 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Correspondence Mozas, Pablo Rivas-Delgado, Alfredo Baumann, Tycho Villamor, Neus Ortiz-Maldonado, Valentín Aymerich, Marta Costa, Dolors Navarro, Alba Giné, Eva López-Guillermo, Armando Montserrat, Emili Delgado, Julio Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia |
| title | Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia |
| title_full | Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia |
| title_fullStr | Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia |
| title_full_unstemmed | Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia |
| title_short | Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia |
| title_sort | analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802533/ https://www.ncbi.nlm.nih.gov/pubmed/29339727 http://dx.doi.org/10.1038/s41408-017-0044-5 |
| work_keys_str_mv | AT mozaspablo analysisofcriteriafortreatmentinitiationinpatientswithprogressivechroniclymphocyticleukemia AT rivasdelgadoalfredo analysisofcriteriafortreatmentinitiationinpatientswithprogressivechroniclymphocyticleukemia AT baumanntycho analysisofcriteriafortreatmentinitiationinpatientswithprogressivechroniclymphocyticleukemia AT villamorneus analysisofcriteriafortreatmentinitiationinpatientswithprogressivechroniclymphocyticleukemia AT ortizmaldonadovalentin analysisofcriteriafortreatmentinitiationinpatientswithprogressivechroniclymphocyticleukemia AT aymerichmarta analysisofcriteriafortreatmentinitiationinpatientswithprogressivechroniclymphocyticleukemia AT costadolors analysisofcriteriafortreatmentinitiationinpatientswithprogressivechroniclymphocyticleukemia AT navarroalba analysisofcriteriafortreatmentinitiationinpatientswithprogressivechroniclymphocyticleukemia AT gineeva analysisofcriteriafortreatmentinitiationinpatientswithprogressivechroniclymphocyticleukemia AT lopezguillermoarmando analysisofcriteriafortreatmentinitiationinpatientswithprogressivechroniclymphocyticleukemia AT montserratemili analysisofcriteriafortreatmentinitiationinpatientswithprogressivechroniclymphocyticleukemia AT delgadojulio analysisofcriteriafortreatmentinitiationinpatientswithprogressivechroniclymphocyticleukemia |